000177405 001__ 177405
000177405 005__ 20240229133739.0
000177405 0247_ $$2doi$$a10.1016/j.canep.2021.102054
000177405 0247_ $$2pmid$$apmid:34773768
000177405 0247_ $$2ISSN$$a1877-7821
000177405 0247_ $$2ISSN$$a1877-783X
000177405 0247_ $$2altmetric$$aaltmetric:116873620
000177405 037__ $$aDKFZ-2021-02497
000177405 041__ $$aEnglish
000177405 082__ $$a610
000177405 1001_ $$aBoakye, Daniel$$b0
000177405 245__ $$aAssociations between comorbidities and advanced stage diagnosis of lung, breast, colorectal, and prostate cancer: A systematic review and meta-analysis.
000177405 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2021
000177405 3367_ $$2DRIVER$$aarticle
000177405 3367_ $$2DataCite$$aOutput Types/Journal article
000177405 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1637077357_5622$$xReview Article
000177405 3367_ $$2BibTeX$$aARTICLE
000177405 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000177405 3367_ $$00$$2EndNote$$aJournal Article
000177405 520__ $$aComorbidities and advanced stage diagnosis (ASD) are both associated with poorer cancer outcomes, but the association between comorbidities and ASD is poorly understood. We summarized epidemiological evidence on the association between comorbidities and ASD of selected cancers in a systematic review and meta-analysis. We searched PubMed and Web of Science databases up to June 3rd, 2021 for studies assessing the association between comorbidities and ASD of lung, breast, colorectal, or prostate cancer. Summary odds ratios (ORs) and 95% confidence intervals (95%CIs) were calculated using random-effects models. Also, potential variations in the associations between comorbidities and ASD by cancer type were investigated using random-effects meta-regression. Thirty-seven studies were included in this review, including 8,069,397 lung, breast, colorectal, and prostate cancer patients overall. The Charlson comorbidity index score was positively associated with ASD (stages III-IV) of breast cancer but was inversely associated with ASD of lung cancer (pinteraction = 0.004). Regarding specific comorbidities, diabetes was positively associated with ASD (OR = 1.17, 95%CI = 1.09-1.26), whereas myocardial infarction was inversely associated with ASD (OR = 0.84, 95%CI = 0.75-0.95). The association between renal disease and ASD differed by cancer type (pinteraction < 0.001). A positive association was found with prostate cancer (OR = 2.02, 95%CI = 1.58-2.59) and an inverse association with colorectal cancer (OR = 0.84, 95%CI = 0.70-1.00). In summary, certain comorbidities (e.g., diabetes) may be positively associated with ASD of several cancer types. It needs to be clarified whether closer monitoring for early cancer signs or screening in these patients is reasonable, considering the problem of over-diagnosis particularly relevant in patients with short remaining life expectancy such as those with comorbidities. Also, evaluation of the cost-benefit relationship of cancer screening according to the type and severity of comorbidity (rather than summary scores) may be beneficial for personalized cancer screening in populations with chronic diseases.
000177405 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000177405 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000177405 650_7 $$2Other$$aAdvanced stage
000177405 650_7 $$2Other$$aCancer
000177405 650_7 $$2Other$$aChronic disease
000177405 650_7 $$2Other$$aComorbidity
000177405 650_7 $$2Other$$aLate-stage
000177405 7001_ $$aGünther, Kathrin$$b1
000177405 7001_ $$0P:(DE-He78)20dc4ad11ff465acf5b99f1e679e10b7$$aNiedermaier, Tobias$$b2$$udkfz
000177405 7001_ $$aHaug, Ulrike$$b3
000177405 7001_ $$aAhrens, Wolfgang$$b4
000177405 7001_ $$aNagrani, Rajini$$b5
000177405 773__ $$0PERI:(DE-600)2498032-8$$a10.1016/j.canep.2021.102054$$gVol. 75, p. 102054 -$$p102054$$tCancer epidemiology$$v75$$x1877-7821$$y2021
000177405 909CO $$ooai:inrepo02.dkfz.de:177405$$pVDB
000177405 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)20dc4ad11ff465acf5b99f1e679e10b7$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000177405 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000177405 9141_ $$y2021
000177405 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER EPIDEMIOL : 2019$$d2021-01-28
000177405 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-28
000177405 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-28
000177405 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-28
000177405 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-28
000177405 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-28
000177405 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000177405 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-28
000177405 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-28
000177405 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-28
000177405 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000177405 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-28
000177405 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-01-28
000177405 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000177405 980__ $$ajournal
000177405 980__ $$aVDB
000177405 980__ $$aI:(DE-He78)C070-20160331
000177405 980__ $$aUNRESTRICTED